CAD and neoplasm: Xenograft tumors with the heterozygous CAD-D1371A mutation demonstrated approximately 25% increased resistance to 5-FU compared to wildtype CAD (evidenced by the tumor volume); however, this resistance was less pronounced than that observed in homozygous mutations, which exhibited about 47% resistance (Fig. 4g, h and Supplementary Fig. 4n, o).